Usefulness of Staging Chest CT in Breast Cancer: Evaluating Diagnostic Yield of Chest CT According to the Molecular Subtype and Clinical Stage
The aim of this study is to investigate the clinical utility of staging chest CT in breast cancer by evaluating diagnostic yield (DY) of chest CT in detection of metastasis, according to the molecular subtype and clinical stage. This retrospective study included 840 patients with 855 breast cancers...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-02-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/10/5/906 |
| _version_ | 1797395323230879744 |
|---|---|
| author | Seulgi You Tae Hee Kim Doo Kyoung Kang Kyung Joo Park Young-Sil An Joo Sung Sun |
| author_facet | Seulgi You Tae Hee Kim Doo Kyoung Kang Kyung Joo Park Young-Sil An Joo Sung Sun |
| author_sort | Seulgi You |
| collection | DOAJ |
| description | The aim of this study is to investigate the clinical utility of staging chest CT in breast cancer by evaluating diagnostic yield (DY) of chest CT in detection of metastasis, according to the molecular subtype and clinical stage. This retrospective study included 840 patients with 855 breast cancers from January 2017 to December 2018. The number of patients in clinical stage 0/I, II, III and IV were 457 (53.5%), 298 (34.9%), 92 (10.8%) and 8 (0.9%), respectively. Molecular subtype was identified in 841 cancers and there were 709 (84.3%) luminal type, 55 (6.5%) human epidermal growth factor receptor 2 (HER2)-enriched type and 77 (9.2%) triple-negative (TN) type. The DYs in clinical stage 0/I, cII, cIII and cIV were 0.2% (1/457), 1.7% (5/298), 4.3% (4/92) and 100.0% (8/8), respectively. The DYs in luminal type, HER2-enriched type and TN type were 1.7% (12/709), 3.6% (2/55) and 2.6% (2/77), respectively. Clinical stage was associated with the DY (<i>p</i> = 0.000). However, molecular subtype was not related to the DY (<i>p</i> = 0.343). Molecular subtype could not provide useful information to determine whether staging chest CT should be performed in early-stage breast cancer. However, chest CT should be considered in advanced breast cancer. |
| first_indexed | 2024-03-09T00:32:49Z |
| format | Article |
| id | doaj.art-c1d3c95231354cfdb3d6101753162d3e |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-09T00:32:49Z |
| publishDate | 2021-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-c1d3c95231354cfdb3d6101753162d3e2023-12-11T18:24:58ZengMDPI AGJournal of Clinical Medicine2077-03832021-02-0110590610.3390/jcm10050906Usefulness of Staging Chest CT in Breast Cancer: Evaluating Diagnostic Yield of Chest CT According to the Molecular Subtype and Clinical StageSeulgi You0Tae Hee Kim1Doo Kyoung Kang2Kyung Joo Park3Young-Sil An4Joo Sung Sun5Department of Radiology, Ajou University School of Medicine, Suwon 16499, KoreaDepartment of Radiology, Ajou University School of Medicine, Suwon 16499, KoreaDepartment of Radiology, Ajou University School of Medicine, Suwon 16499, KoreaDepartment of Radiology, Ajou University School of Medicine, Suwon 16499, KoreaDepartment of Nuclear Medicine and Molecular Imaging, Ajou University School of Medicine, Suwon 16499, KoreaDepartment of Radiology, Ajou University School of Medicine, Suwon 16499, KoreaThe aim of this study is to investigate the clinical utility of staging chest CT in breast cancer by evaluating diagnostic yield (DY) of chest CT in detection of metastasis, according to the molecular subtype and clinical stage. This retrospective study included 840 patients with 855 breast cancers from January 2017 to December 2018. The number of patients in clinical stage 0/I, II, III and IV were 457 (53.5%), 298 (34.9%), 92 (10.8%) and 8 (0.9%), respectively. Molecular subtype was identified in 841 cancers and there were 709 (84.3%) luminal type, 55 (6.5%) human epidermal growth factor receptor 2 (HER2)-enriched type and 77 (9.2%) triple-negative (TN) type. The DYs in clinical stage 0/I, cII, cIII and cIV were 0.2% (1/457), 1.7% (5/298), 4.3% (4/92) and 100.0% (8/8), respectively. The DYs in luminal type, HER2-enriched type and TN type were 1.7% (12/709), 3.6% (2/55) and 2.6% (2/77), respectively. Clinical stage was associated with the DY (<i>p</i> = 0.000). However, molecular subtype was not related to the DY (<i>p</i> = 0.343). Molecular subtype could not provide useful information to determine whether staging chest CT should be performed in early-stage breast cancer. However, chest CT should be considered in advanced breast cancer.https://www.mdpi.com/2077-0383/10/5/906staging chest CTbreast cancerdiagnostic yieldmolecular subtypeclinical stage |
| spellingShingle | Seulgi You Tae Hee Kim Doo Kyoung Kang Kyung Joo Park Young-Sil An Joo Sung Sun Usefulness of Staging Chest CT in Breast Cancer: Evaluating Diagnostic Yield of Chest CT According to the Molecular Subtype and Clinical Stage Journal of Clinical Medicine staging chest CT breast cancer diagnostic yield molecular subtype clinical stage |
| title | Usefulness of Staging Chest CT in Breast Cancer: Evaluating Diagnostic Yield of Chest CT According to the Molecular Subtype and Clinical Stage |
| title_full | Usefulness of Staging Chest CT in Breast Cancer: Evaluating Diagnostic Yield of Chest CT According to the Molecular Subtype and Clinical Stage |
| title_fullStr | Usefulness of Staging Chest CT in Breast Cancer: Evaluating Diagnostic Yield of Chest CT According to the Molecular Subtype and Clinical Stage |
| title_full_unstemmed | Usefulness of Staging Chest CT in Breast Cancer: Evaluating Diagnostic Yield of Chest CT According to the Molecular Subtype and Clinical Stage |
| title_short | Usefulness of Staging Chest CT in Breast Cancer: Evaluating Diagnostic Yield of Chest CT According to the Molecular Subtype and Clinical Stage |
| title_sort | usefulness of staging chest ct in breast cancer evaluating diagnostic yield of chest ct according to the molecular subtype and clinical stage |
| topic | staging chest CT breast cancer diagnostic yield molecular subtype clinical stage |
| url | https://www.mdpi.com/2077-0383/10/5/906 |
| work_keys_str_mv | AT seulgiyou usefulnessofstagingchestctinbreastcancerevaluatingdiagnosticyieldofchestctaccordingtothemolecularsubtypeandclinicalstage AT taeheekim usefulnessofstagingchestctinbreastcancerevaluatingdiagnosticyieldofchestctaccordingtothemolecularsubtypeandclinicalstage AT dookyoungkang usefulnessofstagingchestctinbreastcancerevaluatingdiagnosticyieldofchestctaccordingtothemolecularsubtypeandclinicalstage AT kyungjoopark usefulnessofstagingchestctinbreastcancerevaluatingdiagnosticyieldofchestctaccordingtothemolecularsubtypeandclinicalstage AT youngsilan usefulnessofstagingchestctinbreastcancerevaluatingdiagnosticyieldofchestctaccordingtothemolecularsubtypeandclinicalstage AT joosungsun usefulnessofstagingchestctinbreastcancerevaluatingdiagnosticyieldofchestctaccordingtothemolecularsubtypeandclinicalstage |